Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination.

MLA

Herishanu, Yair, et al. “Efficacy of a Third BNT162b2 MRNA COVID-19 Vaccine Dose in Patients with CLL Who Failed Standard 2-Dose Vaccination.” Blood, vol. 139, no. 5, Feb. 2022, pp. 678–85. EBSCOhost, https://doi.org/10.1182/blood.2021014085.

APA

Herishanu, Y., Rahav, G., Levi, S., Braester, A., Itchaki, G., Bairey, O., Dally, N., Shvidel, L., Ziv-Baran, T., Polliack, A., Tadmor, T., & Benjamini, O. (2022). Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination. Blood, 139(5), 678–685. https://doi.org/10.1182/blood.2021014085

Chicago

Herishanu, Yair, Galia Rahav, Shai Levi, Andrei Braester, Gilad Itchaki, Osnat Bairey, Najib Dally, et al. 2022. “Efficacy of a Third BNT162b2 MRNA COVID-19 Vaccine Dose in Patients with CLL Who Failed Standard 2-Dose Vaccination.” Blood 139 (5): 678–85. doi:10.1182/blood.2021014085.